FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising a wild-type cytomegalovirus (CMV) glycoprotein B (gB) engineered mutant for inducing an immune response to CMV, a nucleic acid molecule for producing a CMV gB protein mutant, a pharmaceutical composition for use as a vaccine for treating or preventing CMV infection in a subject, a method for inducing an immune response against CMV infection in a subject and a method for preventing CMV infection in a subject. In one embodiment, the engineered wild-type cytomegalovirus (CMV) protein B (gB) mutant comprises at least two engineered disulphide mutations selected from a group consisting of: D217C and Y589C; M371C and W506C; and N524C and M684C, wherein the numbering of the constructed mutation is given relative to SEQ ID NO: 1.
EFFECT: invention extends the range of agents for inducing an immune response to CMV.
34 cl, 26 dwg, 17 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| INFLUENZA HEMAGGLUTININ COMPOSITIONS WITH HETEROLOGOUS EPITOPES AND/OR ALTERED CLEAVAGE SITES DURING MATURATION | 2017 |
|
RU2769406C2 |
| IL2 AND MUTANT TNF IMMUNOCONJUGATES | 2017 |
|
RU2758139C2 |
| ANTIGEN-BINDING PROTEINS AGAINST TIGIT AND THEIR APPLICATION METHODS | 2018 |
|
RU2776714C2 |
| COMPOSITIONS RELATED TO MUTANT TOXIN CLOSTRIDIUM DIFFICILE AND THEIR APPLICATION METHODS | 2017 |
|
RU2773880C1 |
| MODIFIED NON-NATURAL NKG2D LIGANDS WHICH SELECTIVELY DELIVER ATTACHED HETEROLOGOUS MOLECULES TO NON-NATURAL NKG2D RECEPTORS ON CAR CELLS | 2020 |
|
RU2823728C2 |
| EMBODIMENTS OF IGG-Fc FOR USE IN VETERINARY SCIENCE | 2018 |
|
RU2814952C2 |
| PSEUDO-FAB BASED MULTISPECIFIC BINDING PROTEINS | 2019 |
|
RU2820254C2 |
| F RSV PROTEIN MUTANTS | 2016 |
|
RU2788403C2 |
| MODULATION OF REP PROTEIN ACTIVITY WHEN PRODUCING CLOSED-END DNA (ceDNA) | 2020 |
|
RU2812850C2 |
